We will begin the MacroGenics fourth quarter and full year 2024 corporate progress and financial results conference call in just a moment. All participants are in a listen-only mode, and we will ...

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China ...

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating ...

The pathologic tumor response (pTR) rate increased from 41.6% with single-agent nivolumab (Opdivo) to 63.6% with nivolumab plus the CTLA-4 inhibitor ipilimumab (Yervoy) and 73.3% with nivolumab ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

So what makes botensilimab different is that the CTLA-4 end is very similar to other CTLA-4 inhibitors that are out there, but it's been engineered on the back end of the molecule that binds to Fc ...

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

In the fourth episode of a six-part interview series on immunotherapy, Marc Voigt, CEO and Executive Director of Immutep (ASX ...